The report entitled Global Long Acting Injectable Anti-psychotic Market: Size, Trends & Forecasts (2017-2021), provides analysis of the global injectable anti-psychotic market, with detailed analysis of market size and growth, and segmentation of the industry.
The report also includes a detailed regional analysis of the long acting injectable anti-psychotic market in the region of the US. Under competitive landscape, different products in the long acting injectable anti-psychotic market have been compared on the basis of different parameters such as dosing frequency, patent expiry, injection sites, label, storage, needles and available strengths. Also, a financial comparison of long acting injectable market players in the US has been done.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global long acting injectable anti-psychotic market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Download Sample Copy Of this Report : http://www.marketresearchreports.biz/sample/sample/1064495
Johnson & Johnson, Eli Lily and Company, Alkermes Public Limited Company and Lundbeck are some of the key players operating in the global long acting injectable anti-psychotic market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Johnson & Johnson
Eli Lily and Company
Alkeremes Public Limited Company
Anti-psychotic refers to a class of medicine used for the treatment of psychosis and various other emotional and mental conditions. Psychosis consist of delusions, hallucinations, paranoia and disordered thought. It is a condition in which a person experiences thought disorder and personality changes. Long acting injectable anti-psychotics are a sub type of antipsychotics which were primarily developed to improve the treatment of schizophrenia.
The global long acting injectable anti-psychotic market can be studied on the basis of different products and on the basis of prescription. These products are different types of long acting injectable anti-psychotic namely Invega Sustenna/ Trinza, Risperdal Consta, Abilify Maintena, Zyprexa, Aristada and many more.
The global long acting injectable anti-psychotic market is expected to increase at a healthy rate during the forecast period (2017-2021). The global long acting injectable anti-psychotic market is supported by various growth drivers, such as increasing cases of schizophrenia, rising number of bipolar disorder patients and non adherence to oral anti-psychotic.
However, side effect associated with anti-psychotic and patent expiry of some of the leading brands are some of the challenges faced by the market. Aging dernography, grant of approval to Trevicta in European Commission, third party proprietary technologies and label expansion of Abilify Maintena are some of the latest trends in the global long acting injectable anti-psychotic market.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org